• Birinapant (TL32711) for Apoptosis Assay Design

  2026-08-26

  Build more informative cancer-cell death studies by pairing Birinapant (TL32711) with TNF, TRAIL, or chemoradiation models. This workflow connects IAP antagonism with the MDM1–p53 apoptosis biology reported in colorectal cancer, while emphasizing controls, timing, and troubleshooting.

• Bifidobacterium, FMT, and PET in Chronic HE

  2026-08-26

  This 2025 study used regional [18F]PBR146 micro-PET/CT to compare Bifidobacterium and fecal microbiota transplantation in bile duct ligation rats with chronic hepatic encephalopathy. Although global brain uptake, behavior, and cytokine measurements were not significantly different, regional imaging suggested that Bifidobacterium may reduce neuroinflammation while FMT produced no clear benefit.

• SERCA-ER Stress and Hematopoietic Stem Cell Mobilization

  2026-08-25

  Li et al. show that pharmacological SERCA inhibition with BHQ can enhance hematopoietic stem cell mobilization in mice by linking ER stress to the CaMKII-STAT3-CXCR4 axis. The study provides a mechanistic framework for investigating calcium-dependent regulation of HSC retention and for designing more precise mobilization experiments.

• Urolithin A: Designing Mitochondrial Assays

  2026-08-25

  Urolithin A is a gut microbiota-derived metabolite that connects mitophagy, mitochondrial metabolism, and cellular stress biology. This article translates mechanistic findings from liver-fibrosis research into a rigorous framework for designing and interpreting Urolithin A experiments without overstating cross-domain evidence.

• Rucaparib and the Next DNA-Repair Question

  2026-08-24

  Rucaparib (AG-014699, PF-01367338) offers a precise way to interrogate PARP1-dependent DNA repair, radiosensitization, and cell-death biology. This thought-leadership perspective connects repair persistence with transcriptional vulnerability while outlining a transport-aware, translational experimental strategy.

• Biomimetic Chromatography for Lung Permeability

  2026-08-24

  This 2025 study compares immobilised artificial membrane liquid chromatography and open-tubular capillary electrochromatography, both coupled with mass spectrometry, as biomimetic models of pulmonary drug permeability. Its findings show that IAM-LC provides useful partition-related prediction, while OT-CEC-MS adds complementary information about lipid composition, charge, and drug–membrane interactions.

• OCT2 and MATE1 Inhibition by 5-HT3 Antagonists

  2026-08-23

  The reference study provides a head-to-head in vitro analysis of how five 5-HT3 antagonists affect renal OCT2 and MATE1 transport, identifying substantial differences in transporter selectivity and potency. Its two-cell-model design connects antiemetic pharmacology with potential drug–drug interaction mechanisms involving renal secretion of organic cations.

• Auranofin, Redox Stress, and Mechanotransduction

  2026-08-22

  A translational perspective on how Auranofin-driven thioredoxin reductase inhibition can be evaluated alongside apoptosis, radiosensitization, and cytoskeleton-dependent autophagy. The article connects established product benchmarks with a clearly bounded mechanistic hypothesis for cancer and antimicrobial research.

• FOXO3/YAP Metabolic Targeting in HCC

  2026-08-22

  The reference study identifies FOXO3 as a tumor-suppressive regulator that concurrently restrains glycolysis and glutaminolysis in hepatocellular carcinoma through direct repression of YAP. Its combination of mechanistic promoter analysis, metabolic phenotyping, in vivo validation, and patient-derived organoids supports the FOXO3/YAP axis as a potential strategy for overcoming metabolic adaptability in HCC.

• PARP7, STAT1/2, and EAE: Mechanistic Insights

  2026-08-21

  The 2025 Cell Reports study identifies PARP7 as a suppressor of type I interferon signaling that ADP-ribosylates STAT1 and STAT2, promoting their ubiquitination and p62-dependent autophagic degradation. Inhibition of PARP7 restored interferon pathway activity and reduced experimental autoimmune encephalomyelitis in mice, providing a mechanistic rationale for investigating this axis in multiple sclerosis research.

• CSBTA Pharmacokinetics in MASH: Key Study Insights

  2026-08-20

  The reference study integrates plasma pharmacokinetics, tissue distribution, cellular transport, microsomal metabolism, and regulatory protein expression to explain why Corydalis saxicola Bunting total alkaloids behave differently in HFHCD-induced MASH mice. Its findings show disease- and dose-dependent increases in systemic exposure and hepatic accumulation, providing a framework for more cautious dosing and pharmacokinetic interpretation in MASLD/MASH research.

• AZD2461: Rethinking PARP Inhibitor Response

  2026-08-20

  A translational perspective on AZD2461 as a novel PARP inhibitor, emphasizing DNA repair pathway modulation, response metrics, Pgp-associated resistance, and biomarker-aware study design in breast cancer research.

• PAD4-IN-2 TFA: Reliable Assay Design

  2026-08-19

  This scenario-based guide explains how PAD4-IN-2 TFA (SKU C8757) can improve interpretation of viability, proliferation, migration, H3cit, and NET assays. It connects reported biochemical and preclinical data with practical controls, dosing considerations, storage guidance, and vendor-selection criteria.

• Quantifying Fractional Killing by High-Throughput Microscopy

  2026-08-19

  Inde, Rodencal, and Dixon present a longitudinal high-throughput microscopy protocol for measuring the fraction of cells killed by anticancer treatments rather than relying only on population-average viability. The workflow combines fluorescent live-cell counting with dead-cell labeling to compare many treatment conditions and reveal variability in MEK1/2 inhibitor-induced killing.

• Multiplexed ACE2 Libraries Reveal SARS-CoV-2 Receptor Shifts

  2026-08-18

  Shukla and colleagues developed a barcoded pseudotyped-virus assay that measures how multiple ACE2 sequences support entry by SARS-CoV-2 spike variants in parallel. The study shows that variant spikes produce modest changes in human ACE2 usage but much larger, variant-specific shifts across animal ACE2 orthologs, clarifying how viral evolution can alter cross-species compatibility.

8520 records 1/568 page Next 12345 下5页 Last page